Výpis publikací

KRISHNA, Shwetha; Aleš OBRDLÍK; Praveenkumar RENGARAJ; Veronika ŠEMBEROVÁ RÁJECKÁ; Anton ZUEV; Helena PESCHELOVÁ; Veronika KOZLOVÁ; Michal ŠMÍDA; David POTĚŠIL; Jana DOBROVOLNÁ a Štěpánka VAŇÁČOVÁ. Adenosine (de)methylation on the crossroads of RNA and DNA synthesis. In Microsymposium on RNA Biology, Vienna, 2025. 2025.

GOTTUMUKKALA, Narendra Varma; Jakub POSPÍŠIL a Michal ŠMÍDA. FORMATION OF TUNNELING NANOTUBES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED MITOCHONDRIAL TRANSFER TRIGGER (CAR)-T CELL EXHAUSTION. In EHA2025 congress, Italy. 2025.

KRISHNA, Shwetha; Aleš OBRDLÍK; Anton ZUEV; Praveenkumar RENGARAJ; Maria ZLOBINA; Helena PESCHELOVÁ; Veronika KOZLOVÁ; Michal ŠMÍDA; Jana DOBROVOLNÁ a Štěpánka VAŇÁČOVÁ. FTO m6A RNA demethylase is important for proper DNA replication in human cells, TALK, Heidelberg, The epitranscriptome. In EMBO workshop: The Epitranscriptome, Heidelberg. 2025.

MARTÍN MOYANO, Paula; Tadeáš KUBINA; Štěpán Owen PARUCH; Aneta JAROŠKOVÁ; Jan NOVOTNÝ; Veronika SKOČKOVÁ; Petra OVESNÁ; Tereza SUCHÁNKOVÁ; Polina PROKOFEVA; Bernhard KUSTER; Michal ŠMÍDA; Apirat CHAIKUAD; Andreas KRÄMER; Stefan KNAPP; Karel SOUČEK a Kamil PARUCH. Thieno[3,2-b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode. Angewandte Chemie International Edition. Wiley, 2025, roč. 64, č. 1, s. "e202412786", 11 s. ISSN 1433-7851. Dostupné z: https://doi.org/10.1002/anie.202412786.

ŠTIKA, Jiří; Michaela PEŠOVÁ; Kateřina STAŇO KOZUBÍK; Magdalena SKALNÍKOVÁ; Lenka DOSTÁLOVÁ; Tomáš LOJA; Lenka RADOVÁ; Veronika PALUŠOVÁ; Kamila RÉBLOVÁ; Zuzana VRZALOVÁ; Ivona BLAHÁKOVÁ; Jakub TRIZULJAK; Stjepan ULDRIJAN; Jan BLATNÝ; Michal ŠMÍDA; Šárka POSPÍŠILOVÁ a Michael DOUBEK. A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study. British journal of haematology. Hoboken: Wiley-Blackwell, 2024, roč. 205, č. 6, s. 2450-2458. ISSN 0007-1048. Dostupné z: https://doi.org/10.1111/bjh.19694.

STYLIANOU, Filio; Adriana LADUNGOVÁ; Jan HÝL; Daniel BUŠA; Martin ČULEN; Barbora WEINBERGEROVÁ; Jiří MAYER a Michal ŠMÍDA. ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

BOBROWICZ, Malgorzata; Aleksandra KUSOWSKA; Marta KRAWCZYK; Andriy ZHYLKO; Christopher FORCADOS; Aleksander SLUSARCZYK; Joanna BARANKIEWICZ; Joanna DOMAGALA; Matylda KUBACZ; Michal ŠMÍDA; Lenka DOSTÁLOVÁ; Katsiaryna MARHELAVA; Klaudyna FIDYT; Monika PEPEK; Iwona BARANOWSKA; Anna SZUMERA-CIECKIEWICZ; Else Marit INDERBERG; Sebastien WALCHLI; Monika GRANICA; Agnieszka GRACZYK-JARZYNKA; Martyna MAJCHRZAK; Marcin POREBA; Carina Lynn GEHLERT; Matthias PEIPP; Malgorzata FIRCZUK; Monika PROCHOREC-SOBIESZEK a Magdalena WINIARSKA. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies. Oncoimmunology. Philadelphia: Taylor & Francis, 2024, roč. 13, č. 1, s. 1-12. ISSN 2162-402X. Dostupné z: https://doi.org/10.1080/2162402X.2024.2362454.

LADUNGOVÁ, Adriana; Filio STYLIANOU; Helena PESCHELOVÁ; Yusuf LODHI; Lenka DOSTÁLOVÁ; Narendra Varma GOTTUMUKKALA a Michal ŠMÍDA. EXPLORING VENETOCLAX RESISTANCE MECHANISMS IN AML CELLS THROUGH GENOME-WIDE CRISPR SCREENS AND DRUG PROFILING. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

JANOVSKÁ, Pavlína; Tomasz Witold RADASZKIEWICZ; P PROCHAZKOVA; Ingrid PRIŠTICOVÁ; Hana PLEŠINGEROVÁ; Martin ČULEN; Michal ŠMÍDA; Daniel BUŠA; Adriana LADUNGOVÁ; Lukáš MAIER; Štěpán HAVEL; Jiří MAYER; A SCHEER; Kamil PARUCH a Vítězslav BRYJA. Novel casein kinase 1 alpha inhibitors for the treatment of resistant AML and solid tumors. In 36th European-Organisation-for-Research-and-Treatment-of-Cancer / National-Cancer-Institute / American-Association-for-Cancer-Research Symposium on Molecular Targets and Cancer Therapeutics (EORTC/NCI/AACR). 2024. Dostupné z: https://doi.org/10.1016/j.ejca.2024.114893.

PESCHELOVÁ, Helena; Veronika MANČÍKOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

ŠMÍDA, Michal. Efficacy of CD19-directed CAR-T cells against CLL and the possibilities for its further improvements. In XVIII. Myeloma VI. Cell Therapy Workshop – MCTW 2023. 2023.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood. 2023.

ŠTIKA, Jiří; Zuzana VRZALOVÁ; Kateřina STAŇO KOZUBÍK; Michaela PEŠOVÁ; Veronika PALUŠOVÁ; Lenka DOSTÁLOVÁ; Ivona BLAHÁKOVÁ; Lenka RADOVÁ; Michal ŠMÍDA; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Funkční efekt nově identifikované varianty v genu CYCS u rodiny s trombocytopenií typu 4. In 23. Pražské hematologické dny, Praha. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

GOTTUMUKKALA, Narendra Varma; Aneta LEDEREROVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Yusuf LODHI a Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity py preventing CD19 antigen escape in relapsed models. In EHA Meeting – 5th European CAR T-cell Meeting, Rotterdam, Nizozemsko. 2023.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Tomáš LOJA a Michal ŠMÍDA. Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. In XX. International Workshop on CLL (iwCLL 2023), Boston, USA. 2023.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In 23. Pražské hematologické dny, Praha. 2023.

ŠTIKA, Jiří; Zuzana VRZALOVÁ; Kateřina STAŇO KOZUBÍK; Michaela PEŠOVÁ; Veronika PALUŠOVÁ; Lenka DOSTÁLOVÁ; Ivona BLAHÁKOVÁ; Lenka RADOVÁ; Michal ŠMÍDA; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Nově identifikovaná varianta v genu CYCS u rodiny s trombocytopenií typu 4 a její funkční dopad. In 25. celostátní konference DNA diagnostiky. 2023.

ŠTIKA, Jiří; Zuzana VRZALOVÁ; Kateřina STAŇO KOZUBÍK; Michaela PEŠOVÁ; Veronika PALUŠOVÁ; Lenka DOSTÁLOVÁ; Ivona BLAHÁKOVÁ; Lenka RADOVÁ; Petra SEDLÁKOVÁ; Radim SONNEK; Michal ŠMÍDA; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Varianta v genu CYCS způsobující trombocytopenii 4 zvyšuje kaspázovou aktivitu. In 56. Výroční cytogenomická konference, Ostrava. 2023.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022.

SKALNÍKOVÁ, Magdalena; Kateřina STAŇO KOZUBÍK; Jakub TRIZULJAK; Zuzana VRZALOVÁ; Lenka RADOVÁ; Kamila RÉBLOVÁ; Radka HOLBOVÁ; Terézia KURUCOVÁ; Hana SVOZILOVÁ; Jiří ŠTIKA; Ivona BLAHÁKOVÁ; Barbara DVOŘÁČKOVÁ; Marie PRUDKOVÁ; Olga STEHLÍKOVÁ; Michal ŠMÍDA; Leoš KŘEN; Petr SMEJKAL; Šárka POSPÍŠILOVÁ a Michael DOUBEK. A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, roč. 23, č. 2, s. 1-13. ISSN 1422-0067. Dostupné z: https://doi.org/10.3390/ijms23020885.

DOSTÁLOVÁ, Lenka; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Narendra Varma GOTTUMUKKALA; Yusuf LODHI a Michal ŠMÍDA. Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. In EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013. 2022.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Helena PESCHELOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In Annual PhD conference Biomedical sciences, Brno. 2022.

DOSTÁLOVÁ; LEDEREROVÁ; PESCHLOVÁ a Michal ŠMÍDA. CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In PhD retreat 2022, Telč. 2022.

LODHI, Yusuf; Adriana LADUNGOVÁ; Daniel BUŠA; Helena PESCHELOVÁ; Martin ČULEN a Michal ŠMÍDA. Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML. In Annual PhD conference Biomedical sciences, Brno. 2022.

GOTTUMUKKALA, Narendra Varma; Veronika MANČÍKOVÁ; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Yusuf LODHI; Jan VERNER a Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In XVII. Myeloma and Cell Therapy Workshop, Ostrava. 2022.

GOTTUMUKKALA, Narendra Varma; Veronika MANČÍKOVÁ; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Yusuf LODHI; Jan VERNER a Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In Annual PhD conference Biomedical sciences, Brno. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

DAVE, Zankruti; Olga VONDÁLOVÁ BLANÁŘOVÁ; Štěpán ČADA; Pavlína JANOVSKÁ; Nikodém ZEZULA; Martin BĚHAL; Kateřina HANÁKOVÁ; Sri Ranjani GANJI; Pavel KREJČÍ; Kristína GÖMÖRYOVÁ; Helena PESCHELOVÁ; Michal ŠMÍDA; Zbyněk ZDRÁHAL; Šárka PAVLOVÁ; Jana KOTAŠKOVÁ; Šárka POSPÍŠILOVÁ a Vítězslav BRYJA. Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Frontiers in Cell and Developmental Biology. Frontiers Media SA, 2022, roč. 10, February 2022, s. 1-11. ISSN 2296-634X. Dostupné z: https://doi.org/10.3389/fcell.2022.838871.

LADUNGOVÁ, Adriana; Daniel BUŠA; Helena PESCHELOVÁ; Yusuf LODHI; Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for CLL and AML cells based on drug repurposing. In CEITEC PhD Conference, Brno. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.

ŠMÍDA, Michal. The use of functional genomics for advancing monoclonal antibody therapy of chronic lymphocytic leukemia. In Alliance4Life thematic miniconference, Smolenice, Slovakia. 2022.

ŠMÍDA, Michal. CD19 hypermethylation as an escape to CART-19. In 3rd European CAR-T cell meeting. 2021.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Veronika MANČÍKOVÁ a Michal ŠMÍDA. CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

ŠMÍDA, Michal. CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cells. In XVI. Myeloma and IV. Cell Therapy Workshop. 2021.

MANČÍKOVÁ, Veronika a Michal ŠMÍDA. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2021, roč. 22, č. 11, s. 5536-5546. ISSN 1422-0067. Dostupné z: https://doi.org/10.3390/ijms22115536.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Veronika KOZLOVÁ a Michal ŠMÍDA. Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

STAŇO KOZUBÍK, Kateřina; Lenka RADOVÁ; Kamila RÉBLOVÁ; Michal ŠMÍDA; Marketa KUBRICANOVA ZALIOVA; Jiří BALOUN; Michaela PEŠOVÁ; Zuzana VRZALOVÁ; František FOLBER; Soňa MEJSTŘÍKOVÁ; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Functional analysis of germlineETV6 W380Rmutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia. Platelets. PHILADELPHIA: TAYLOR & FRANCIS INC, 2021, roč. 32, č. 6, s. 838-841. ISSN 0953-7104. Dostupné z: https://doi.org/10.1080/09537104.2020.1802416.

LEDEREROVÁ, Aneta; Lenka DOSTÁLOVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Martin ČULEN; Tomáš LOJA; Jan VERNER; Šárka POSPÍŠILOVÁ; Michal ŠMÍDA a Veronika MANČÍKOVÁ. Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2021, roč. 9, č. 8, s. 1-8. ISSN 2051-1426. Dostupné z: https://doi.org/10.1136/jitc-2021-002352.

ŠMÍDA, Michal. Identification of biomarkers and escape mechanisms for CAR-T cell therapy in chronic lymphocytic leukemia. In Visegrad meeting. 2021.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Tomáš LOJA; Jan VERNER; Šárka POSPÍŠILOVÁ; Veronika MANČÍKOVÁ a Michal ŠMÍDA. In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

STAŇO KOZUBÍK, Kateřina; Zuzana VRZALOVÁ; Jakub TRIZULJAK; Magdalena SKALNÍKOVÁ; Lenka RADOVÁ; Ivona BLAHÁKOVÁ; Jiří ŠTIKA; Veronika BERGEROVÁ; Michal ŠMÍDA; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Kongenitální neutropenie u dětí a dospělých. Transfúze a hematologie dnes. Mladá fronta a.s., 2021, roč. 27, č. 4, s. 297-303. ISSN 1213-5763. Dostupné z: https://doi.org/10.48095/cctahd2021297.

FAJTLOVÁ, Šárka; Ivan REKTOR; Michal ŠMÍDA a Štěpánka VAŇÁČOVÁ. Open Week. 2021.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Adriana LADUNGOVÁ; Helena PESCHELOVÁ; Pavlína JANOVSKÁ; A. SLUSARCZYK; J. DOMAGALA; Pavel KOPČIL; Viera VAKULOVÁ; Jan OPPELT; Vítězslav BRYJA; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. Plos one. San Francisco: Public Library Science, 2020, roč. 15, č. 3, s. 0229170-229189. ISSN 1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0229170.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Veronika MANČÍKOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Combination of epigenetic drug screen and CRISPR knockout screen as an unbiased approach to reveal possible CD20 therapy improvement. In XXth Interdisciplinary meeting of young researchs and students in the field of chemistry, biochemistry, molecular biology and biomaterials in Chemické listy. 2020.

LEDEREROVÁ, Aneta; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Helena PESCHELOVÁ; J. PERSSON; B. SCHMIERER; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Combination of epigenetic drug screen and CRISPR knockout screen revealed involvement of aurora kinases and Cullin 3 in CD20 regulation. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Adriana LADUNGOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia. In XXth Interdisciplinary meeting of young researchs and students in the field of chemistry, biochemistry, molecular biology and biomaterials in Chemické listy. 2020. ISSN 2336-7202.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Veronika MANČÍKOVÁ; Jiří MAYER; Šárka POSPÍŠILOVÁ; Michael DOUBEK a Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In XVIII. International Workshop on CLL, Edinburgh, Skotsko. 2020. ISSN 1042-8194.

PESCHELOVÁ, Helena; Lenka DOSTÁLOVÁ; Veronika KOZLOVÁ; Aneta LEDEREROVÁ; Václav HEJRET a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.

MANČÍKOVÁ, Veronika; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Impact of genetics on the performance of anti-CD 19 chimeric antigen receptor T cells in chronic lymphocytic leukemia. In 2nd European CAT T Cell Meeting. 2020.

MANČÍKOVÁ, Veronika; Helena PESCHELOVÁ; Veronika KOZLOVÁ; Aneta LEDEREROVÁ; Adriana LADUNGOVÁ; Jan VERNER; Tomáš LOJA; František FOLBER; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2020, roč. 8, č. 1, s. 000471-481. ISSN 2051-1426. Dostupné z: https://doi.org/10.1136/jitc-2019-000471.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Adriana LADUNGOVÁ; Václav HEJRET a Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In CEITEC PhD Conference. 2020.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 gene editing and functional screening in chronic lymphocytic leukemia. In Joint retreat 2019, Kouty u Ledče nad Sázavou. 2019. ISBN 978-80-210-9300-3.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetic drug screen of a CD20-low expressing cell line revealed an unexpected role of Aurora kinase inhibitors in CD20 expression. In 6th Prague-Weizmann Summer School Advances in Drug Discovery, Praha. 2019.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetic drug screen of CD20-low expressing cell line revealed possible treatment target. In Joint retreat 2019, Kouty u Ledče nad Sázavou. 2019.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Veronika MANČÍKOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetic drug screen on CD20 immunotherapy resistant cells revealed possible role of Aurora kinase inhibitors in CD20 expression regulation. In 5th Annual International Conference New Concepts in Lymphoid Malignancies, Estoril, Portugalsko. 2019.

MANČÍKOVÁ, Veronika; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Performance of α-CD19 Chimeric Antigen Receptor T cells in genetically defined classes of Chronic Lymphocytic Leukemia. In 5th Annual International Conference New Concepts in Lymphoid Malignancies, Estoril, Portugalsko. 2019.

ŠMÍDA, Michal. Revoluce v imunoterapii nádorů: CAR-T lymfocyty. In XXIII. Biologické dny 2019 – moderní trendy biomedicínského výzkumu, Brno. 2019.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Václav HEJRET a Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In Biomania, Brno. 2019.

ŠMÍDA, Michal. ASH 2017 – novinky laboratorní. In X. Plenární zasedání ČS CLL, Praha. 2018.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia. In CEITEC PHD and POSTDOC RETREAT. 2018.

PEŠOVÁ, Michaela; Kateřina STAŇO KOZUBÍK; Karol PÁL; Michal ŠMÍDA; Jiří BALOUN; Lenka RADOVÁ; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Dědičné trombocytopenie. Transfuze a Hematologie Dnes. Praha: Ceska Lekarska Spolecnost J.E. Purkyne/Czech Medical Association, 2018, roč. 24, č. 1, s. 14-26, 14 s. ISSN 1213-5763.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets. In Czech Chemical Society Symposium Series in Chemické Listy. 2018.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetic drug screen on resistant CLL cells reveals Aurora kinase inhibitors as enhancers of CD20 expression and sensitizers to treatment with CD20 monoclonal antibodies. In 60th ASH Annual meeting, San Diego, USA in Blood 2018. 2018.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression. 2018.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Epigenetický screening buněk rezistentních k rituximabu odhalil možnou roli inhibitorů Aurora kináz v regulaci exprese CD20. In I. Český hematologický a transfuziologický sjezd, Praha in Transfuze a hematologie dnes. 2018.

ŠMÍDA, Michal. Functional genomics to predict novel targets for personalized therapy of B-cell malignancies. In CEITEC Principal Investigator Seminar. 2018.

ŠMÍDA, Michal; Jiří MAYER a Veronika MANČÍKOVÁ. T lymfocyty s chimerickým receptorem (CAR): revoluce v imunoterapii nádorů. In XIII. Brněnské hematologické dny/Novinky v hematologii, Brno. 2018.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Unexpected role of Aurora kinase inhibitors in CD20 expression. In CEITEC PHD and POSTDOC RETREAT 2018. 2018.

LEDEREROVÁ, Aneta; Veronika KOZLOVÁ; Viera VAKULOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile. In 22nd congress of EHA, Madrid, Španělsko, červen 2017 in Haematologica (2017). 2017.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Viera VAKULOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies. In CEITEC PHD RETREAT II, Telč. 2017.

LEDEREROVÁ, Aneta; Veronika KOZLOVÁ; Viera VAKULOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. In EMBO Practical Course: Current Methods in Cell Biology, Heidelberg, Německo. 2017.

PEŠOVÁ, Michaela; Kateřina STAŇO KOZUBÍK; Karol PÁL; Lenka RADOVÁ; Michal ŠMÍDA; Jiří BALOUN; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Exomové sekvenování v diagnostice dědičných trombocytopenií. In Brněnský genetický den, Brno. 2017.

ŠMÍDA, Michal. Mechanisms of resistance to monoclonal antibodies in CLL. In Scientific and Clinical Preceptorship: Chronic Lymphocytic Leukemia, Brno. 2017.

DE LA CRUZ, F.F.; Michal ŠMÍDA a M. NIJMAN. MEK inhibitors block growth of Ataxia Telangiectasia Mutated (ATM) mutant lung tumors. In AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer. 2017. ISSN 1535-7163. Dostupné z: https://doi.org/10.1158/1538-8514.SYNTHLETH-PR14.

PEŠOVÁ, Michaela; Kateřina STAŇO KOZUBÍK; Karol PÁL; Michal ŠMÍDA; Jiří BALOUN; Zuzana VRZALOVÁ; Lenka RADOVÁ; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Význam a využití NGS v diagnostice dědičných trombocytopenií. In Pražský hematologický den, Praha. 2017.

ŠMÍDA, Michal; Veronika KOZLOVÁ; Viera VAKULOVÁ; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER a Šárka POSPÍŠILOVÁ. Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. In Blood (2016); s. 3968. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016). 2016.

KOZLOVÁ, Veronika; Viera VAKULOVÁ; Aneta LEDEREROVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. In 2nd International Conference on New Concepts in B-Cell Malignancies, Estoril, Portugalsko, září 2016. 2016.

ŠMÍDA, Michal; Ferran Fece DE LA CRUZ; Claudia KERZENDORFER; Iris Z. URAS; Barbara MAIR; Abdelghani MAZOUZI; Tereza SUCHANKOVA; Tomasz KONOPKA; Amanda M. KATZ; Keren PAZ; Katalin NAGY-BOJARSZKY; Markus K. MUELLNER; Zsuzsanna BAGO-HORVATH; Eric B. HAURA; Joanna I. LOIZOU a Sebastian M. B. NIJMAN. MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nature Communications. London: Nature Publishing Group, 2016, roč. 7, December, s. nestránkováno, 13 s. ISSN 2041-1723. Dostupné z: https://doi.org/10.1038/ncomms13701.

ŠMÍDA, Michal. Nové technologie v medicíně: CAR T lymfocyty – převratná metoda v léčbě hematologických malignit. In Novinky v hematologii, Brno. 2016.

LEDEREROVÁ, Aneta; Veronika KOZLOVÁ; Viera VAKULOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Příprava linií rezistentních k působení anti-CD20 monoklonálních protilátek a analýza signálních drah u B-lymfoidních malignit. In Pražský hematologický den, říjen 2016. 2016.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Viera VAKULOVÁ; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Vyřazení genu CD20 pomocí CRISPR/Cas9 knockoutu nezpůsobí žádný defekt v BCR signalizaci u B-lymfoidních malignit. In Pražský hematologický den, říjen 2016. 2016.

STAŇO KOZUBÍK, Kateřina; Karol PÁL; Lenka RADOVÁ; Michal ŠMÍDA; Kamila RÉBLOVÁ; Karla PLEVOVÁ; Šárka POSPÍŠILOVÁ a Michael DOUBEK. Využití celoexomového sekvenování. In XXX. Olomoucké hematologické dny. 2016.

ŠMÍDA, Michal. Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění? Klinická onkologie: časopis České a Slovenské onkologické společnosti. Brno: C̆eská onkologická spolec̆nost Slovenská onkologicka spolecnost, 2015, roč. 28, č. 4, s. "4S44"- "4S47", 4 s. ISSN 0862-495X. Dostupné z: https://doi.org/10.14735/amko20154S44.

DOUBEK, Michael a Michal ŠMÍDA. Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? Expert Review of Hematology. ABINGDON: TAYLOR & FRANCIS LTD, 2015, roč. 8, č. 6, s. 743-764. ISSN 1747-4086. Dostupné z: https://doi.org/10.1586/17474086.2015.1079123.

VAKULOVÁ, Viera; Michael DOUBEK; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Vplyv terapie monoklonálnými protilátkami u chronickej lymfocytovej leukémie a B-lymfómov na expresiu antigénu CD20. In XVII. Slovensko-český hematologický a transfuziologický zjazd, Bratislava, Slovensko. 2015.